A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Psoriasis
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2015
At a glance
- Drugs Brodalumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Amgen
- 28 Jul 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 Mar 2015 According to an Amgen media release, data from this study were presented at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) 2015.
- 14 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record